​

ADC Therapeutics SA (ADCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ADCT Stock Forecast

ADC Therapeutics SA (ADCT) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $9.33, with a high of $13.00 and a low of $7.00. This represents a 436.21% increase from the last price of $1.74.

- $3 $6 $9 $12 $15 High: $13 Avg: $9.33 Low: $7 Last Closed Price: $1.74

ADCT Stock Rating

ADC Therapeutics SA stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (57.14%), 3 Hold (42.86%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 3 4 Strong Sell Sell Hold Buy Strong Buy

ADCT Price Target Upside V Benchmarks

TypeNameUpside
StockADC Therapeutics SA436.21%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$10.50
Last Closing Price$1.74$1.74$1.74
Upside/Downside--503.45%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25241--7
Jan, 25241--7
Dec, 24241--7
Nov, 24241--7
Oct, 24241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2024Robert BurnsH.C. Wainwright$8.00$4.4579.78%359.77%
Mar 13, 2024Kelly ShiJefferies$13.00$3.90233.33%647.13%
Nov 14, 2022Morgan Stanley$7.00$4.1070.73%302.30%
Sep 09, 2022Matthew HarrisonMorgan Stanley$11.00$6.5268.71%532.18%
Aug 22, 2022H.C. Wainwright$20.00$8.42137.53%1049.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 30, 2024Cantor FitzgeraldOverweightinitialise
May 07, 2024H.C. WainwrightBuyBuyhold
Feb 20, 2024NeedhamBuyBuyhold
Aug 10, 2023Deutsche BankHolddowngrade
Nov 14, 2022Morgan StanleyEqual-WeightEqual-Weighthold
Sep 19, 2022H.C. WainwrightBuyBuyhold
May 10, 2022RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.77$-3.00$-2.38$-2.94-----
Avg Forecast$-3.53$-3.44$-2.07$-2.39$-1.71$-1.54$-1.18$-0.90$-0.33
High Forecast$-3.91$-3.82$-2.18$-2.54$-1.89$-1.82$-1.70$-1.32$-0.35
Low Forecast$-3.34$-3.26$-1.98$-2.14$-1.42$-1.19$-0.86$-0.67$-0.31
Surprise %6.80%-12.79%14.98%23.01%-----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$33.92M$209.91M$69.56M-----
Avg Forecast$1.29M$33.01M$187.67M$68.07M$72.72M$81.02M$113.22M$177.00M$268.70M
High Forecast$1.23M$31.66M$181.53M$67.64M$72.41M$78.98M$113.22M$172.32M$257.73M
Low Forecast$1.39M$35.78M$195.08M$68.37M$73.03M$83.54M$113.22M$181.68M$282.60M
Surprise %-2.75%11.85%2.18%-----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-246.29M$-230.03M$-155.80M$-240.05M-----
Avg Forecast$-288.28M$-281.21M$-169.14M$-191.38M$-135.25M$-122.75M$-104.59M$-81.30M$-27.13M
High Forecast$-319.73M$-311.88M$-177.82M$-207.62M$-154.22M$-148.66M$-138.91M$-107.86M$-28.95M
Low Forecast$-272.99M$-266.29M$-161.95M$-175.15M$-116.29M$-96.84M$-70.27M$-54.75M$-25.69M
Surprise %-14.57%-18.20%-7.89%25.43%-----

ADCT Forecast FAQ

Is ADC Therapeutics SA stock a buy?

ADC Therapeutics SA stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ADC Therapeutics SA is a favorable investment for most analysts.

What is ADC Therapeutics SA's price target?

ADC Therapeutics SA's price target, set by 7 Wall Street analysts, averages $9.33 over the next 12 months. The price target range spans from $7 at the low end to $13 at the high end, suggesting a potential 436.21% change from the previous closing price of $1.74.

How does ADC Therapeutics SA stock forecast compare to its benchmarks?

ADC Therapeutics SA's stock forecast shows a 436.21% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for ADC Therapeutics SA over the past three months?

  • February 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is ADC Therapeutics SA’s EPS forecast?

ADC Therapeutics SA's average annual EPS forecast for its fiscal year ending in December is $-1.71 for 2024, a -41.84% decrease from the reported $-2.94 in 2023. The prediction for 2025 is $-1.54, $-1.18 for 2026, $-0.9 for 2027, and $-0.33 for 2028.

What is ADC Therapeutics SA’s revenue forecast?

ADC Therapeutics SA's average annual revenue forecast for its fiscal year ending in December is $72.72M for 2024, a 4.54% increase from the reported $69.56M in 2023. The forecast for 2025 is $81.02M, $113.22M for 2026, $177M for 2027, and $268.7M for 2028.

What is ADC Therapeutics SA’s net income forecast?

For its fiscal year ending in December, ADC Therapeutics SA's average annual net income forecast is $-135M for 2024, reflecting a -43.66% decrease from the reported $-240M in 2023. The projection for 2025 is $-123M, $-105M for 2026, $-81.304M for 2027, and $-27.128M for 2028.